Bafna Pharmaceuticals Ltd
₹105.11
(-4.44%)
Sat, 14 Mar 2026, 00:31 am
Health Technology
Pharmaceuticals: Major
24.5KBafna Pharmaceuticals Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 24.33 | 24.42 | 20.91 | 45.29 | 17.87 | 22.67 | 8.97 | 0 | 0 | 0 | 0 | 0 | 55.74 | 57.59 | 17.24 | 24.68 | 42.73 |
| Price to book ratio | 0 | 0 | 0 | 0.68 | 1.48 | 1.41 | 1.36 | 1.06 | 0.46 | 0.77 | 0.97 | 1.29 | 1.75 | 1.36 | 0.04 | 5.72 | 4.85 | 2.66 | 2.24 | 2.09 |
| Price to sales ratio | 0 | 0 | 0 | 0.57 | 0.81 | 0.69 | 0.66 | 0.41 | 0.17 | 0.55 | 0.65 | 0.85 | 1.44 | 0.59 | 0.05 | 4.56 | 3.53 | 1.69 | 1.19 | 1.22 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.84 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31.12 | 59.34 | 24.85 | 9.08 |
| Enterprise value | 0 | 0 | 0 | 443.33M | 884.42M | 1.09B | 1.67B | 1.53B | 1.39B | 1.22B | 1.34B | 1.34B | 1.08B | 692.12M | -63.84M | 3.36B | 3.11B | 2.11B | 2.04B | 2.02B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 8.94 | 11.40 | 9.52 | 10.41 | 6.70 | 5.56 | 0 | 107.07 | 0 | 0 | 0 | -4.97 | 32.52 | 25.96 | 13.39 | 18.01 | 17.69 |
| Debt to equity ratio | 2.02 | 0.92 | 1.92 | 0.53 | 0.73 | 0.94 | 1.34 | 1.50 | 1.59 | 0.96 | 1.39 | 1.93 | 1.23 | 2.43 | 0 | 0.23 | 0.18 | 0.31 | 0.30 | 0.33 |
| Return on equity % | 18.58 | 4.75 | 4.79 | 4.24 | 6.24 | 7.03 | 3.12 | 6.04 | 2.06 | 8.78 | -21.66 | -38.01 | -41.53 | -69.77 | -5.37 | 10.80 | 8.79 | 16.63 | 9.52 | 5.01 |
Bafna Pharmaceuticals Ltd Enterprise Value
The Bafna Pharmaceuticals Ltd Enterprise Value is a key financial metric used by investors to evaluate Bafna Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Bafna Pharmaceuticals Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Bafna Pharmaceuticals Ltd (NSE: BAFNAPH, BSE: 532989) is currently trading at ₹105.11, with a market capitalization of ₹2.52B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Bafna Pharmaceuticals Ltd Enterprise Value is essential for fundamental analysis.
Bafna Pharmaceuticals Ltd Enterprise Value Current Value
The current Bafna Pharmaceuticals Ltd Enterprise Value stands at 2.02B.
The Bafna Pharmaceuticals Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Bafna Pharmaceuticals Ltd Enterprise Value Historical Trend
The Bafna Pharmaceuticals Ltd Enterprise Value has shown the following historical trend:
- 2024: 2.02B
- 2023: 2.04B
- 2022: 2.11B
- 2021: 3.11B
- 2020: 3.36B
The decline in Bafna Pharmaceuticals Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Bafna Pharmaceuticals Ltd Enterprise Value Indicates for Investors
The Bafna Pharmaceuticals Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Bafna Pharmaceuticals Ltd.
Bafna Pharmaceuticals Ltd Enterprise Value Analysis Summary
The Bafna Pharmaceuticals Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Bafna Pharmaceuticals Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Bafna Pharmaceuticals Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800